Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer drops Neurocrine deal
July 3, 2006
| A version of this story appeared in
Volume 84, Issue 27
Neurocrine and Pfizer have ended a four-year-old partnership to develop Neurocrine's sleep-enhancement drug indiplon. Neurocrine will reacquire worldwide rights to the drug. The split follows notification from FDA in May that 5- and 10-mg indiplon capsules are approvable, but only with data reanalysis and possible additional studies. The 15-mg extended-release tablets were deemed not approvable. Neurocrine's stock dove 60% after that announcement and dropped another 27% on June 23 on news of the split with Pfizer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X